Breaking Down SG&A Expenses: GSK plc vs Alnylam Pharmaceuticals, Inc.

A Comparative Analysis of SG&A Expenses: GSK plc vs Alnylam Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, GSK plc and Alnylam Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, GSK's SG&A expenses have consistently been over 10 times higher than Alnylam's, reflecting its larger scale and market presence. However, Alnylam has demonstrated a remarkable growth trajectory, with its SG&A expenses increasing by over 1,600% from 2014 to 2023. This surge highlights Alnylam's aggressive expansion and investment in its operations. Meanwhile, GSK's expenses peaked in 2020, followed by a slight decline, indicating strategic cost management. This analysis provides a window into the financial strategies of these pharmaceutical giants, offering insights into their operational priorities and market strategies.